Podder 2020.

Study characteristics
Methods	Trial design: open‐label RCT with 2 parallel arms Type of publication: journal publication Setting: outpatient Recruitment dates: May to July 2020 Country: Bangladesh Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NA Date of registration: NA
Participants	Number of participants (randomized/analyzed): 82/62 Age (mean): overall 39 (SD 12.07) years Males, n: overall 44 (71%) Severity of condition according to study definition: outpatients with mild‐to‐moderate disease Severity of condition according to WHO scale: 2 to 3 Co‐morbidities: NR Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) Inclusion criteria: RT‐PCR positive; mild‐to‐moderate COVID‐19; aged > 18 years; either sex Exclusion criteria: known pre‐existing hypersensitivity to ivermectin; pregnant and lactating mothers; receiving other antimicrobials or hydroxychloroquine
Interventions	Details of intervention Type and dose: ivermectin 0.2 mg/kg, single dose Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care including antipyretics, cough suppressants, and capsule doxycycline (100 mg every 12 hours for 7 days) administered in both study arms Duration of follow‐up: until symptom resolution Treatment cross‐overs: none
Outcomes	Primary study outcome Not defined Relevant review outcomes reported Duration to symptom resolution (from enrolment) Viral clearance at 10 days Additional study outcomes reported Duration of individual symptoms (fever, cough, shortness of breath, myalgia, fatigue) Duration to symptom resolution (from illness onset)
Notes	Date of publication: July 2020 Sponsor/funding: 'self financed' Information on ethics votum: no name of responsible ethics committee, reference number of proposal, or votum provided in publication. Sent author request; no response received